FDA starts review of Cubist Pharma antibiotic
Cubist says FDA will make a decision on its skin infection treatment tedizolid by June 20
LEXINGTON, Mass. (AP) -- Federal regulators have accepted an experimental antibiotic from Cubist Pharmaceuticals for expedited review, the company said Monday.
That means that a decision on Tedizolid could come from the Food and Drug Administration by June 20.
The antibiotic designed to treat serious skin infections. Cubist acquired tedizolid when it bought Trius Therapeutics in September. The deal was valued around $818 million.
Shares of Cubist Pharmaceuticals Inc. rose 12 cents to $67.48 in morning trading.
